Method of treating apoptosis and compositions thereof

• US 7,829,662 B2
• Filed: 06/15/2007
• Issued: 11/09/2010
• Est. Priority Date: 12/31/2001
• Status: Expired due to Fees

• Current Assignee: Dana-Farber Cancer Institute
• Original Assignee: Dana-Farber Cancer Institute
• Inventors: Scorrano, Luca, Korsmeyer, Stanley J.
• Primary Examiner(s): Yu; Misook
• Assistant Examiner(s): Halvorson; Mark
• Application Number:
  US11/818,915
• Publication Number:
  US 20080097081A1
• Time in Patent Office: 1,243 Days
• Field of Search: None
• US Class Current: 530/300
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/4747 Apoptosis related proteins

Abstract

Disclosed herein are novel polypeptides and the nucleic acid sequences that encode them. Also disclosed are antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders involving these novel human nucleic acids and proteins.

Claims

1. An isolated BID mutein polypeptide comprising the amino acid sequence of SEQ ID NO:

8 or 9, wherein said BID-mutein contacts a cell and decreases mitochondrial inner membrane remodeling, decreases cytochrome c mobilization, or decreases apoptosis.

3. The isolated polypeptide of claim 1 or 2, wherein said polypeptide does not dimerize with BAX, BCL-2 or BCL-X.

2. An isolated polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:

8 and 9.

4. An isolated BID mutein polypeptide of less than or equal to 50 amino acids in length comprising the sequence of SEQ ID NO:

8 or 9.